Last updated 2026-07-26
- Went public on TSXV (NRX), Jul 2022
- Raised $643k Undisclosed Round, Mar 2026
- Raised $2.3M PIPE led by Jay Richardson, Sep 2025
Total raised
$12.0M
Last: PIPE 2026-06
Stage
Public
Founded
2020
Headcount
30
HQ
Haifa, Israel
Sector
Health Tech & Life Sciences
About
NurExone Biologic is a biopharmaceutical company focused on developing and commercializing regenerative exosome-based therapies for central nervous system (CNS) injuries. Its proprietary ExoTherapy platform utilizes exosome-loaded nanodrugs, designed to leverage the natural ability of exosomes to reach damaged or inflamed tissue for targeted delivery of therapeutic compounds. The company's lead product candidate, ExoPTEN, is being developed for the treatment of acute spinal cord injury and optic nerve damage. NurExone operates with a focus on advancing its pipeline through preclinical validation, CMC readiness, and regulatory milestones, with the goal of initiating first-in-human clinical trials.
Funding history · 10 rounds · $12.0M total
2026-03
Undisclosed Round
$643K
2025-09
PIPE
$2.3M
★ Jay Richardson★ James Richardson
2025-04
PIPE
$1.7M
2025-01
PIPE
$838K
★ other participants★ James A. Richardson
2025-01
Undisclosed Round
Undisclosed
2024-09
PIPE
$1.2M
2024-08
PIPE
$2.0M
2023-07
PIPE
$530K
2022-06
Follow-on PO
Undisclosed
2022-04
PIPE
$2.8M
Headcount over time
From 2 (2021-06) to 28 (2025-12) · +26 (+1300%) · 24 points · source: Finder history + radar grounding
Q&A
- What is NurExone Biologic's primary focus?
- NurExone Biologic is a biopharmaceutical company developing and commercializing regenerative exosome-based therapies for central nervous system (CNS) injuries. Their lead product candidate, ExoPTEN, targets acute spinal cord injury and optic nerve damage.
- When did NurExone Biologic go public?
- NurExone Biologic went public on the TSXV in July 2022 through a Reverse Takeover Transaction.
- What was NurExone Biologic's most recent funding round?
- NurExone Biologic completed a PIPE funding round in June 2026, raising $458,000.
- What is the current employee count for NurExone Biologic?
- NurExone Biologic has 11-50 employees.
- What is the latest patent news for NurExone Biologic?
- In September 2025, NurExone received a U.S. patent allowance for exosome manufacturing, and an Israel Patent Grant for Extracellular Vesicles Production was announced in September 2025.
- What is NurExone Biologic's strategy for U.S. manufacturing?
- In September 2025, NurExone announced plans to establish its first U.S. commercial manufacturing facility in Indiana. Additionally, in February 2025, NurExone formed Exo-Top Inc. in the U.S. for exosome manufacture and commercialization.
- Has NurExone Biologic received any orphan drug designations?
- Yes, NurExone Biologic received FDA Orphan-Drug Designation for its ExoPTEN therapy for Acute Spinal Cord Injury Treatment in October 2023, and EMA Orphan Status for ExoPTEN in Spinal Cord Injury in November 2024.
- What recent preclinical study results has NurExone Biologic announced for ExoPTEN?
- In September 2024, NurExone demonstrated an extended therapeutic window of ExoPTEN post spinal-cord injury in a preclinical study. In October 2025, NurExone also demonstrated reproducible, dose-dependent vision recovery in a preclinical glaucoma model.
- What is NurExone Biologic's plan for clinical trials for acute spinal cord injury therapy?
- In May 2025, NurExone announced clinical trial plans for acute spinal cord injury therapy at the Annual Meeting of the American Spinal Injury Association.
- What is NurExone Biologic's market capitalization?
- NurExone Biologic has a market capitalization of $38,683,281 USD.
Team · 3
Yoram Drucker
Founder · Co-Founder
Daniel Offen
Founder · Co-Founder
Shulamit Levenberg
Founder · Co-Founder
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
neurosciencecns-disordersnon-invasivepharmaceuticalsdrug-discovery
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | nurexone.com/ |
|---|---|
| linkedin.com/company/72446905 | |
| facebook.com/NurExone | |
| YouTube | youtube.com/@nurexonebiologic737 |
Identifiers & details
| Legal name | NurExone Biologic Inc. |
|---|---|
| Founded | 2020-1 |
| Employees (exact) | 30 |
| Market cap | $38.7M |
| Status reason | Public on TSXV on Jul 2022; |
Acquisitions & public offerings
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| Reverse Takeover Transaction | 2022-07 | TSXV | NRX |
Radar intelligence
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 516209202 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2020-06-17 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 1 — charge (1) |
| Registered address | פארק תעשיה גוטווירט הטכניון ב חיפה |
Recent registry events
| Date | Event |
|---|---|
| 2026-04-12 | סילוק שעבוד |